Predictors of improvement in left ventricular function after initially successful angioplasty of unprotected left

Fang-Bin Hu1, Hideo Tamai, Kunihiko Kosuga

  • 1Department of Cardiology, Shiga Medical Center for Adults, Moriyama, Shiga, Japan.

Insights

Percutaneous coronary intervention (PCI) improves left ventricular ejection fraction (LVEF), particularly in patients with reduced baseline LVEF. This study identifies factors influencing LVEF changes after PCI for unprotected left main coronary artery lesions.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Percutaneous coronary intervention (PCI) is increasingly used for unprotected left main coronary artery (LMCA) lesions.
  • The impact of PCI on left ventricular (LV) performance remains incompletely understood.
  • No studies have identified factors influencing left ventricular ejection fraction (LVEF) post-PCI in these patients.

Purpose of the Study:

  • To evaluate the effect of PCI on LVEF in patients with unprotected LMCA lesions.
  • To identify clinical and procedural factors associated with LVEF improvement after PCI.

Main Methods:

  • A cohort of 199 patients undergoing de novo PCI for unprotected LMCA stenoses between April 1986 and August 2002.
  • Clinical and angiographic follow-up, including paired left ventriculography for LVEF assessment.

Main Results:

  • LVEF significantly improved post-PCI (52.9% to 56.1%, p=0.048).
  • Greater LVEF improvement was observed in patients with baseline LVEF ≤50% (6.7% increase) compared to those with LVEF >50% (0.7% increase).
  • Baseline LVEF ≤50% was the sole independent predictor of LVEF improvement (p<0.001).

Conclusions:

  • Successful PCI for unprotected LMCA lesions is associated with significant LVEF improvement.
  • Patients with pre-existing depressed LV function (LVEF ≤50%) experience the most substantial LVEF gains.
Abstract

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...